1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J Clin mai,2021
2. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer [Internet]. http://dx.doi.org/10.1056/NEJMoa0802656. 2009 [cité 22 juill 2019]. Disponible sur: https://www.nejm.org/doi/10.1056/NEJMoa0802656?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov.
3. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck;Ferris;N Engl J Med,2016
4. EMA. Opdivo [Internet]. European Medicines Agency. 2018 [cité 30 sept 2022]. Disponible sur: https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo.
5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;The Lancet.,2019